Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

Ipilimumab/nivolumab demonstrated a significantly longer OS at the 12-month milestone and an acceptable toxicity profile. Our results therefore underline a relevant clinical benefit of ipilimumab/nivolumab in previously untreated nccRCC entities compared to current SOC.

Authors

Institutions

Publication Details

Journal
Annals of Oncology
Published
2025-04-03
DOI
https://doi.org/10.1016/j.annonc.2025.03.016
Citations
29
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
44.03

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

Aude Fléchon, Viktor Grünwald, Marc‐Oliver Grimm, Begoña Mellado et al.
29 citations
Annals of Oncology
Renal cell carcinoma treatment
44.03
article

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

Aude Fléchon, Viktor Grünwald, Marc‐Oliver Grimm, Begoña Mellado, Franck Priou, Ekaterini Boleti, Marine Gross‐Goupil, J.B.A.G. Haanen, Stefan Siemer, Daniel Castellano, Philipp Ivanyi, Sjoukje F. Oosting, Philippe Barthélémy, Stefanie Zschäbitz, Pablo Maroto, Florence Joly, Sylvie Rottey, Marit Ahrens, Jindřich Kopecký, Arndt Hartmann, Dorothee Deckbar, M. Retz, Anne Flörcken, Gwénaëlle Gravis, Laurence Albigès, Cristina Suárez, Jens Bedke, Tomáš Büchler, Peter J. Goebell, Günter Niegisch, Tom Waddell, L. Bergmann, Martin Boegemann, U. Zimmermann, Iris Burkholder
article en
29 citations

Abstract

Ipilimumab/nivolumab demonstrated a significantly longer OS at the 12-month milestone and an acceptable toxicity profile. Our results therefore underline a relevant clinical benefit of ipilimumab/nivolumab in previously untreated nccRCC entities compared to current SOC.

Annals of OncologyVol. 36(7)
Goethe University Frankfurt (DE), Hebron University (PS), Centre National de la Recherche Scientifique (FR), University Medical Center Groningen (NL), Inserm (FR), Royal Free London NHS Foundation Trust (GB), University of Groningen (NL), Fulda University of Applied Sciences (DE), Charles University (CZ), Heidelberg University (DE), Universitätsmedizin Greifswald (DE), Ghent University Hospital (BE), Hospital de Sant Pau (ES), Institut Gustave Roussy (FR), University Hospital Heidelberg (DE), TUM Klinikum (DE), The Netherlands Cancer Institute (NL), Centre Hospitalier Universitaire de Bordeaux (FR), Medizinische Hochschule Hannover (DE), Humboldt-Universität zu Berlin (DE), Universitätsklinikum Erlangen (DE), Düsseldorf University Hospital (DE), Institut de Cancérologie Strasbourg (FR), University Hospital Münster (DE), Centre Léon Bérard (FR), Immunité et Cancer (FR), Oncode Institute (NL), Hospital Clínic de Barcelona (ES), Hospital Universitario HM Madrid (ES), Essen University Hospital (DE), Centre François Baclesse (FR), Vall d'Hebron Hospital Universitari (ES), University Hospital Frankfurt (DE), The Christie NHS Foundation Trust (GB), Jena University Hospital (DE), University Hospital Hradec Králové (CZ), Thomayer University Hospital (CZ), Centre Hospitalier Départemental Vendée (FR), Comprehensive Cancer Center Erlangen (DE), Klinikum Stuttgart (DE), Heinrich Heine University Düsseldorf (DE), Technical University of Munich (DE), University of Tübingen (DE), Saarland University (DE)
Bristol-Myers Squibb, Clinical Trial Center, China Medical University Hospital, European Society for Medical Oncology, AIO-Studien
Zero hunger
Openalex Percentile: Top 0%
Renal cell carcinoma treatment
44.03
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.